Adjuvant developed with NIH funding enhances efficacy of India's COVID-19 vaccine
(NIH/National Institute of Allergy and Infectious Diseases) An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
More News: Allergy | Allergy & Immunology | COVID-19 | Funding | India Health | Infectious Diseases | National Institutes of Health (NIH) | Vaccines